• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Head and Neck Cancer Therapy De-Escalation: A “Salutary Lesson”

  • — 12 Nov, 2018
Head and Neck Cancer Therapy De-Escalation: A “Salutary Lesson”
Hisham Mehanna PhD ARCS warns not to "de-escalate" therapy for head and neck cancer.
Audio Journal of Oncology Podcast
Audio Journal of Oncology Podcast
Head and Neck Cancer Therapy De-Escalation: A “Salutary Lesson”
Head and Neck Cancer Therapy De-Escalation: A “Salutary Lesson”
00:00 / 5 minutes
Apple Podcasts Spotify Stitcher
RSS Feed
Share
Link
Embed

Subscribe: Apple Podcasts | Spotify | Stitcher

MUNICH—A “salutary lesson” was reported by researchers investigating therapy for oropharyngeal cancer at the 2018 annual congress of the European Society for Medical Oncology (ESMO). It came from results of the De-ESCALaTE HPVstudy that found patients with low-risk head and neck cancer who tested positive for human papilloma virus (HPV+) did better if they had been treated with standard platinum-based chemotherapy (added their radiotherapy) rather than the epidermal growth factor receptor (EGFR) inhibitor cetuximab.

https://cslide.ctimeetingtech.com/esmo2018/attendee/confcal/session/calendar?q=+LBA9_PR

Phase three trials needed

“One of the big lessons is that you really need phase three trials—even when treatments are already approved—as in [the] case [of] head and neck cancer,” said Hisham Mehanna PhD BMed Sci FRCS, Chair of Head and Neck Surgery at the Institute for Head and Neck Studies Education in the University of Birmingham, UK. “You need phase three trials to compare new treatments to standards of care to really be able to take [them] into the clinic,” he told the Audio Journal of Oncology. “Clinical practice should not be changed without these phase three trials.”

Detriment from cetuximab

TheDe-ESCALaTE HPV study—reported at ESMO by Mehanna and his colleagues—found there had been “significant detriment from the use of cetuximab instead of cisplatin in terms of tumor control and no benefit in terms of reduced toxicity. They concluded that: “Cisplatin and radiotherapy remained the standard of care in this setting.”

You may also like...

  • Andrew Loblaw Low risk localized prostate cancer: no harm from waiting! 16 Mar, 2013
  • Cabozantinib Improved Hepatocellular Carcinoma Survival Beyond Sorafenib Cabozantinib Improved Hepatocellular Carcinoma Survival Beyond Sorafenib 15 Oct, 2018
  • Lugano Audio Journal of Oncology with Oncology Times, June 2013 13 Jun, 2013
  • Oncology Times Broadcast News with the Audio Journal of Oncology – February 2009 Oncology Times Broadcast News with the Audio Journal of Oncology – February 2009 9 Feb, 2009
  • Previous story Which New Combination for Metastatic Renal Cell Cancer?
  • Next story Ibrutinib: New Frontline Standard for Chronic Lymphocytic Leukemia?
  • News

    • Liquid Biopsy ctDNA Prediction of Lung Cancer Relapse “Ready for Prime Time”Liquid Biopsy ctDNA Prediction of Lung Cancer Relapse “Ready for Prime Time”August 4, 2022
    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
  • Related interviews

    • Ibrutinib: New Frontline Standard for Chronic Lymphocytic…
    • Microbiome Diversity Key To Survival After Allogeneic…
    • Genomic-led AML Clinical Decision Making Within Seven Days
    • New Front Line Standard for Older Patients with Chronic…
    • Volume CT Lung Cancer Screening Cuts Cancer Deaths 24 Per…
  • Home
  • Oncology
  • AJO
  • Head and Neck Cancer Therapy De-Escalation: A “Salutary Lesson”

© Copyright 2022 AudioMedica.com. Typegrid Theme by WPBandit.